|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001779,
umls-concept:C0005532,
umls-concept:C0012634,
umls-concept:C0023467,
umls-concept:C0030705,
umls-concept:C0038952,
umls-concept:C0087111,
umls-concept:C0205375,
umls-concept:C0332293,
umls-concept:C0439234,
umls-concept:C1521761
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2005-5-5
|
|
pubmed:abstractText |
The objectives of the current study were to evaluate the outcome of patients > or = 60 years with acute myeloid leukemia (AML) treated uniformly with high-dose daunorubicin containing induction and modified high-dose cytosine arabinoside containing postremission therapy, and to identify factors predictive of complete disease remission (CR) and survival.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
103
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2082-90
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:15830348-Acute Disease,
pubmed-meshheading:15830348-Age Factors,
pubmed-meshheading:15830348-Aged,
pubmed-meshheading:15830348-Aged, 80 and over,
pubmed-meshheading:15830348-Antibiotics, Antineoplastic,
pubmed-meshheading:15830348-Antimetabolites, Antineoplastic,
pubmed-meshheading:15830348-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15830348-Cytarabine,
pubmed-meshheading:15830348-Daunorubicin,
pubmed-meshheading:15830348-Disease-Free Survival,
pubmed-meshheading:15830348-Female,
pubmed-meshheading:15830348-Follow-Up Studies,
pubmed-meshheading:15830348-Hematologic Diseases,
pubmed-meshheading:15830348-Humans,
pubmed-meshheading:15830348-Karyotyping,
pubmed-meshheading:15830348-L-Lactate Dehydrogenase,
pubmed-meshheading:15830348-Leukemia, Myeloid,
pubmed-meshheading:15830348-Leukocyte Count,
pubmed-meshheading:15830348-Male,
pubmed-meshheading:15830348-Middle Aged,
pubmed-meshheading:15830348-Myelodysplastic Syndromes,
pubmed-meshheading:15830348-Remission Induction,
pubmed-meshheading:15830348-Retrospective Studies,
pubmed-meshheading:15830348-Survival Rate,
pubmed-meshheading:15830348-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
|
|
pubmed:affiliation |
Department of Medical Oncology and Hematology, Princess Margaret Hospital/University Health Network, Toronto, Ontario, Canada.
|
|
pubmed:publicationType |
Journal Article
|
